Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)